Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed Kostaive®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries).

Website

http://www.arcturusrx.com

External link for Arcturus Therapeutics

Industrie

Biotechnology Research

Größe des Unternehmens

51-200 Mitarbeiter

Hauptsitz

San Diego, CA

Typ

Öffentliches Unternehmen

Gegründet

2013

Spezialitäten

mRNA, Lipid-Mediated Delivery, Rare Diseases, OTC Deficiency, Cystic Fibrosis, Vaccines, Therapeutics, HBV, Coronavirus, COVID-19, Lipids, LUNAR, STARR, Innovation, Discovery, Leadership, Partnerships, RNA, Development, mRNA medicine, and Glycogen Storage disease